Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(510)
•••
Comment by 2b7f6fabon Jun 24, 2019 2:08pm
121 Views
Post# 29856928

RE:RE:RE:FOMO

RE:RE:RE:FOMOA Ph2 trial in the USA only makes sense if the FDA gives guidance to wave Ph3 with a certain amount of success in Ph2 ahead of time.  Why spend money in the USA if TLT would still need a Ph3?  Get HC marketing approval with a Ph2 and maybe the EU and China.  I would travel to Canada to save my bladder.

vestor111 wrote: Three news AM's before the AGM...

Here's the ultimate triple play:

TLT announces some number of patients treated while training docs from several new centers around Canada.   Three birds...one stone.  

After that announced FDA filing/approval.  With several US docs trained including Dr Kamat and Dr O'Donnell.   

Neither would be impossible releases to hear this week.  

My wish list is longer but that will do for now.  (I would like to be surprised.) 




Bullboard Posts
Dealroom for high-potential pre-IPO opportunities